Income Majors: Legal & General, GSK and Hill & Smith Under Review
Investors' Chronicle's annual Income Majors special turns to two FTSE 100 dividend names and a mid-cap manufacturer. Legal & General, the insurer, is under pressure from a more competitive pensions market, and attention is on the chief executive's buyback plan and the income it supports. GSK, formerly GlaxoSmithKline, is managing a difficult balance between returning cash to shareholders and funding an expensive oncology push.
GSK has spent £18bn this year alone on research and development to build its oncology pipeline, according to the podcast. That scale of spending raises questions about how much room remains for dividend growth. Legal & General's issue is different: competition in the pensions market is squeezing a business that has long been an income favourite.
Hill & Smith, the steel products group, is the third name discussed. It now generates two-thirds of revenue from the US and has switched its reporting currency from sterling to dollars, a sign of where its growth is concentrated.
The Trade-offs Behind Two FTSE 100 Dividends and a US Pivot
Legal & General: A Buyback in a Competitive Pensions Market
Pressure in the pensions market is the central concern for Legal & General. The company's response, via the chief executive's buyback plan, suggests management is prioritising capital returns rather than chasing growth in a contested market. For income investors, a buyback can support per-share metrics, but it does not by itself repair the competitive position that the podcast highlights.
GSK: £18bn R&D Versus Dividend Reliability
An £18bn annual R&D spend is an aggressive bet on oncology, and it sits alongside dividend obligations. The balancing act is whether the pipeline produces enough new revenue before the spending erodes the income case. The discussion presents this tension as the defining issue for GSK investors.
Hill & Smith: Two-Thirds US and a Dollar Reporting Currency
Generating two-thirds of revenue in the US and moving to dollar reporting reduces sterling dependence and changes the group's currency profile. That is a structural shift, not a one-off, and it matters for UK investors assessing currency exposure in their holdings.
What the Three Stories Mean for Income Investors
- For Legal & General, ask whether the buyback addresses the pensions market competition or only supports near-term shareholder returns; the competitive pressure is the unresolved issue in the discussion.
- For GSK, weigh the £18bn R&D spend against dividend growth expectations; the oncology pipeline is the key source of future revenue but is not yet proven in the material reviewed.
- For Hill & Smith, treat the two-thirds US revenue and dollar reporting as a currency and geographic exposure change, not simply a growth story.
Risk & Opportunity Assessment
| Commercial Risk | Medium | Legal & General faces pressure from a more competitive pensions market, while GSK's £18bn R&D outlay tests the balance with dividends. |
| Competitive Risk | Medium | Legal & General's pensions market competition is expressly flagged; Hill & Smith's US shift diversifies revenue but also changes its competitive geography. |
| Regulatory Risk | Low | The podcast does not identify a regulatory action or change; the pressures discussed are commercial and R&D-related. |
| Reputation Risk | Low | No reputational event is described; GSK's challenge is operational capital allocation rather than controversy. |
| Technology Disruption | Low | No direct technology-platform disruption is discussed; GSK's R&D is pipeline development rather than a technology shift. |
| Commercial Opportunity | Medium | GSK's £18bn oncology R&D is aimed at future revenue, and Hill & Smith's two-thirds US revenue positions it for US-linked demand. |
Comments 0